Biohaven Pharmaceutical Ireland DAC

Primary study objective: To compare the efficacy of rimegepant versus placebo for the preventive treatment of migraine by evaluating the mean reduction in monthly migraine days during the entire double-blind treatment period compared to the observation period.

Primary objective: To evaluate the efficacy of rimegepant compared to placebo in the acute treatment of migraine in adolescents (≥ 12 years to < 18 years) by measuring pain freedom 2 hours after dosing. Secondary objective: To evaluate the efficacy of rimegepant compared to placebo in the acute treatment of migraine in a combined population of children and adolescents (≥ 6 years to < 18 years) by measuring pain freedom 2 hours after dosing.

Primary Objective: To evaluate the long-term safety and tolerability of rimegepant ODT 75 mg taken as needed (PRN). Secondary Objective: To evaluate the number of headache days and severity of migraine attacks during long-term treatment with rimegepant ODT 75 mg (PRN) compared to the observation period.